Weight and length at birth and risk of early-onset prostate cancer (United States)

Lori L. Boland, Pamela J. Mink, Sally A. Bushhouse, Aaron R. Folsom

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Objective: A case-control study was conducted to examine the association of weight and length at birth with early-onset prostate cancer. Methods: Cases of prostate cancer diagnosed between 1988 and 1995 (n = 192) were identified through the Minnesota Cancer Surveillance System. Two separate control groups were selected using driver's license (DL) and birth certificate (BC) listings. Results: Using the DL control group, an inverse association was observed between birth weight and prostate cancer risk; adjusted odds ratios (95% confidence intervals) for ≤3000, 3001-3500, 3501-4000, and >4000 g at birth were 1.0, 0.72 (0.4-1.28), 0.58 (0.31-1.10), and 0.49 (0.24-1.00). In analyses using the BC control group, adjusted odds ratios (95% CIs) for the aforementioned birth weight categories were 1.0, 1.18 (0.64-2.18), 0.80 (0.42-1.54), and 1.04 (0.48-2.26), respectively. For both control groups, adjusted odds ratios were somewhat elevated for the upper three categories of birth length, but all confidence intervals included the null value. Conclusions: These findings do not support the hypothesis that greater weight or length at birth increases risk of prostate cancer.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalCancer Causes and Control
Volume14
Issue number4
DOIs
StatePublished - May 2003

Bibliographical note

Funding Information:
The authors wish to thank Ethelyn Yliniemi for locating birth records and abstracting data for this study. This research was supported by the National Cancer Institute Grant R01 CA39742. Pamela Mink was supported by the National Cancer Institute Training Grant T32 09607.

Keywords

  • Birth length
  • Birth weight
  • Prostate cancer

Fingerprint Dive into the research topics of 'Weight and length at birth and risk of early-onset prostate cancer (United States)'. Together they form a unique fingerprint.

Cite this